Clinical Trials
13 trialsNCT04772989 2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1 Completed
NCT03399448 2023-06-22
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
University of Pennsylvania
Phase 1 Terminated
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT01916135 2020-04-27
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00667082 2017-11-22
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Phase 1 Completed
NCT01829971 2016-09-27
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Mirna Therapeutics, Inc.
Phase 1 Terminated
NCT02457650 2016-08-03
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
Phase 1 Unknown
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02369029 2016-03-09
BAY1238097, First in Man
Bayer
Phase 1 Terminated
NCT00161187 2015-11-06
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT00276536 2015-10-14
IFNa
The Cleveland Clinic
Phase 1 Completed
NCT00073944 2013-05-30
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed